市場調査レポート

商品コード

1671137

血液悪性腫瘍治療薬の世界市場：市場規模・シェア・動向、業界分析 (疾患別・治療法別・最終用途別・地域別)、将来予測 (2025年～2034年)

Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Therapy, End Use, and Region - Market Forecast, 2025-2034

出版日: 2025年02月01日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,250 612,255円

レポートPDFを1名のみがご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 5,250 756,315円

レポートPDFを20名様までご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 6,250 900,375円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。ご利用人数に制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Polaris Market Research社の最新調査によると、血液悪性腫瘍治療薬の市場規模は2034年までに1,481億5,000万米ドルに達する見込みです。本レポートでは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

血液悪性腫瘍治療薬は、白血病、リンパ腫、骨髄腫を含む血液がんを管理するために使用される治療法を指します。これらのがんは血液、骨髄、リンパ系、脾臓に影響を及ぼし、専門的な治療アプローチが必要となります。白血病、リンパ腫、骨髄腫などの血液がんの罹患率の増加と治療選択肢の進歩に牽引され、血液悪性腫瘍治療薬市場シェアは著しい成長を遂げています。主な促進要因としては、CAR-T細胞療法やモノクローナル抗体などの免疫療法の台頭や、副作用の少ないより正確な治療を提供する標的療法の採用拡大が挙げられます。また、併用療法の開発、個別化医療、バイオシミラーの拡大など、従来の治療に代わる費用対効果の高い治療法にもビジネスチャンスが生まれています。さらに、現在進行中の研究、臨床試験、新治療法の規制当局による承認が、引き続き市場の技術革新を後押ししています。外来治療へのシフトによる患者アクセスの向上、治療抵抗性の低減への注力といった動向は、市場全体の拡大に寄与しており、今後数年間は継続的な成長が見込まれます。

血液悪性腫瘍治療薬市場：分析概要

白血病は、慢性リンパ性白血病（CLL）や急性骨髄性白血病（AML）などの疾患の高い有病率により、市場シェアで市場を独占しています。標的治療薬の大幅な進歩が成長を牽引しています。しかし、リンパ腫は、CAR-T細胞療法などの免疫療法の採用増加により、最も急速に成長している分野です。

免疫療法は最大の血液悪性腫瘍治療薬市場シェアを占めており、CAR-T細胞療法とモノクローナル抗体が血液悪性腫瘍治療の変革に重要な役割を果たしています。精密治療が血液がん患者の転帰を改善し副作用を軽減し続けていることから、標的治療が最も急成長を記録しています。

病院薬局は、CAR-T細胞療法や化学療法などの複雑な治療を実施する上で中心的な役割を担っているため、最大の市場シェアを占めています。小売薬局は、経口オンコリティクスと在宅治療オプションに対する需要の高まりに支えられ、最も急成長しているセグメントです。

北米は、治療へのアクセス性の高さ、高度なヘルスケア・インフラ、新規治療に対する規制上の支援により市場を独占しています。アジア太平洋は、がん罹患率の増加、ヘルスケアアクセスの改善、治療イノベーションへの投資により、最も急成長している地域です。

市場スナップショット
血液悪性腫瘍治療薬の市場力学
- 促進要因と機会
  - AIと機械学習の統合
  - ハイスループット実験への移行
- 抑制要因と課題
  - データ量の不足
PESTLE分析
血液悪性腫瘍治療薬市場の動向
バリューチェーン分析
COVID-19の影響分析

第5章世界の血液悪性腫瘍治療薬市場：疾患別

主な分析結果
イントロダクション
白血病
リンパ腫
骨髄腫

第6章世界の血液悪性腫瘍治療薬市場：治療法別

主な分析結果
イントロダクション
化学療法
免疫療法
標的療法
その他

第7章世界の血液悪性腫瘍治療薬市場：最終用途別

主な分析結果
イントロダクション
病院薬局
その他

第8章世界の血液悪性腫瘍治療薬市場：地域別

主な分析結果
イントロダクション
- 血液悪性腫瘍治療薬市場の評価：地域別 (2020～2034年)
北米
- 北米：疾病別 (2020～2034年)
- 北米：治療法別 (2020～2034年)
- 北米：最終用途別 (2020～2034年)
- 米国
- カナダ
欧州
- 欧州：疾病別 (2020～2034年)
- 欧州：治療法別 (2020～2034年)
- 欧州：最終用途別 (2020～2034年)
- 英国
- フランス
- ドイツ
- イタリア
- スペイン
- オランダ
- ロシア
- その他欧州
アジア太平洋
- アジア太平洋：疾病別 (2020～2034年)
- アジア太平洋：治療法別 (2020～2034年)
- アジア太平洋：最終用途別 (2020～2034年)
- 中国
- インド
- マレーシア
- 日本
- インドネシア
- 韓国
- オーストラリア
- その他アジア太平洋
中東・アフリカ
- 中東・アフリカ：疾病別 (2020～2034年)
- 中東・アフリカ：治療法別 (2020～2034年)
- 中東・アフリカ：最終用途別 (2020～2034年)
- サウジアラビア
- アラブ首長国連邦
- イスラエル
- 南アフリカ
- その他中東・アフリカ
ラテンアメリカ
- ラテンアメリカ：疾病別 (2020～2034年)
- ラテンアメリカ：治療法別 (2020～2034年)
- ラテンアメリカ：最終用途別 (2020～2034年)
- メキシコ
- ブラジル
- アルゼンチン
- その他ラテンアメリカ

第9章競合情勢

事業拡大・企業買収の分析
- 事業拡大
- 企業買収
提携/協業/合意/公開

第10章企業プロファイル

AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences Inc.
Johnson & Johnson
Novartis AG
Pfizer Inc.
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
AstraZeneca
BeiGene
Kite Pharma（a subsidiary of Gilead Sciences）
Celgene Corporation（acquired by Bristol-Myers Squibb）
Regeneron Pharmaceuticals, Inc.

図表

List of Tables:

Table 1 Global Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 2 Global Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 3 Global Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 4 North America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 5 North America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 6 North America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 7 U.S.: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 8 U.S.: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 9 U.S.: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 10 Canada: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 11 Canada: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 12 Canada: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 13 Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 14 Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 15 Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 16 UK: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 17 UK: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 18 UK: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 19 France: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 20 France: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 21 France: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 22 Germany: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 23 Germany: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 24 Germany: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 25 Italy: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 26 Italy: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 27 Italy: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 28 Spain: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 29 Spain: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 30 Spain: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 31 Netherlands: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 32 Netherlands: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 33 Netherlands: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 34 Russia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 35 Russia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 36 Russia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 37 Rest of Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 38 Rest of Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 39 Rest of Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 40 Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 41 Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 42 Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 43 China: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 44 China: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 45 China: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 46 India: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 47 India: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 48 India: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 49 Malaysia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 50 Malaysia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 51 Malaysia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 52 Japan: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 53 Japan: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 54 Japan: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 55 Indonesia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 56 Indonesia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 57 Indonesia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 58 South Korea: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 59 South Korea: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 60 South Korea: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 61 Australia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 62 Australia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 63 Australia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 64 Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 65 Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 66 Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 67 Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 68 Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 69 Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 70 Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 71 Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 72 Saudi Arabia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 73 UAE: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 74 UAE: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 75 UAE: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 76 Israel: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 77 Israel: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 78 Israel: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 79 South Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 80 South Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 81 South Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 82 Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 83 Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 84 Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 85 Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 86 Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 87 Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 88 Mexico: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 89 Mexico: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 90 Mexico: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 91 Brazil: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 92 Brazil: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 93 Brazil: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 94 Argentina: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 95 Argentina: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 96 Argentina: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
Table 97 Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
Table 98 Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
Table 99 Rest of Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)

List of Figures:

Figure 1. Global Hematologic Malignancies Therapeutics Market, 2020-2034 (USD Billion)
Figure 2. Integrated Ecosystem
Figure 3. Research Methodology: Top-Down & Bottom-Up Price
Figure 4. Market by Geography
Figure 5. Porter's Five Forces
Figure 6. Market by Disease
Figure 7. Global Hematologic Malignancies Therapeutics Market, by Disease, 2024 & 2034 (USD Billion)
Figure 8. Market by Therapy
Figure 9. Global Hematologic Malignancies Therapeutics Market, by Therapy, 2024 & 2034 (USD Billion)
Figure 10. Market by End Use
Figure 11. Global Hematologic Malignancies Therapeutics Market, by End Use, 2024 & 2034 (USD Billion)

Product Code: PM1347

The hematologic malignancies therapeutics market size is expected to reach USD 148.15 billion by 2034, according to a new study by Polaris Market Research. The report "Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease (Leukemia, Lymphoma, and Myeloma), Therapy, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Hematologic malignancies therapeutics refer to the medical treatments used to manage blood cancers, which include leukemia, lymphoma, and myeloma. These cancers affect the blood, bone marrow, lymphatic system, or spleen and require specialized therapeutic approaches. The hematologic malignancies therapeutics market share is experiencing significant growth, driven by increasing incidence rates of blood cancers such as leukemia, lymphoma, and myeloma, alongside advancements in treatment options. Key drivers include the rise of immunotherapies, such as CAR-T cell therapies and monoclonal antibodies, as well as the growing adoption of targeted therapies that offer more precise treatment with fewer side effects. Opportunities are emerging in the development of combination therapies, personalized medicine, and the expansion of biosimilars, providing cost-effective alternatives to traditional treatments. Additionally, ongoing research, clinical trials, and regulatory approvals for new therapies continue to drive innovation in the market. Trends such as a shift toward outpatient care increased patient access, and a focus on reducing treatment resistance contribute to the market's overall expansion, positioning it for continued growth in the coming years.

Hematologic Malignancies Therapeutics Market Report Highlights

Leukemia dominates the market in terms of market share due to the high prevalence of conditions such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Significant advancements in targeted therapies are driving its growth. However, lymphoma is the fastest growing segment, driven by the increasing adoption of immunotherapies such as CAR-T cell therapies.

Immunotherapy holds the largest hematologic malignancies therapeutics market share, with CAR-T cell therapies and monoclonal antibodies playing a crucial role in transforming the treatment of hematologic malignancies. Targeted therapies are registering the fastest growth as precision treatments continue to improve outcomes and reduce side effects in blood cancer patients.

Hospital pharmacies hold the largest market share due to their central role in administering complex treatments such as CAR-T cell therapies and chemotherapy. Retail pharmacies are the fastest growing segment, supported by the rising demand for oral oncolytics and at-home treatment options.

North America dominates the market due to high treatment accessibility, advanced healthcare infrastructure, and regulatory support for new therapies. Asia Pacific is the fastest growing region, fueled by increasing cancer incidence, improving healthcare access, and investment in treatment innovations.

Polaris Market Research has segmented the hematologic malignancies therapeutics market report based on disease, therapy, end use, and region:

By Disease Outlook (Revenue-USD Billion, 2020 - 2034)

Leukemia
Lymphoma
Myeloma

By Therapy Outlook (Revenue-USD Billion, 2020 - 2034)

Chemotherapy
Immunotherapy
Targeted Therapy
Others

By End Use Outlook (Revenue-USD Billion, 2020 - 2034)

Hospital Pharmacies
Retail Pharmacies
Others

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. Global Hematologic Malignancies Therapeutics Market Insights

4.1. Hematologic Malignancies Therapeutics Market - Market Snapshot
4.2. Hematologic Malignancies Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Integration of AI and Machine Learning
  - 4.2.1.2. Shift Toward High-Throughput Experimentation
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Insufficient data volume
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Hematologic Malignancies Therapeutics Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Hematologic Malignancies Therapeutics Market, by Disease

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
5.3. Leukemia
- 5.3.1. Global Hematologic Malignancies Therapeutics Market, by Leukemia, by Region, 2020-2034 (USD Billion)
5.4. Lymphoma
- 5.4.1. Global Hematologic Malignancies Therapeutics Market, by Lymphoma, by Region, 2020-2034 (USD Billion)
5.5. Myeloma
- 5.5.1. Global Hematologic Malignancies Therapeutics Market, by Myeloma, by Region, 2020-2034 (USD Billion)

6. Global Hematologic Malignancies Therapeutics Market, by Therapy

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
6.3. Chemotherapy
- 6.3.1. Global Hematologic Malignancies Therapeutics Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
6.4. Immunotherapy
- 6.4.1. Global Hematologic Malignancies Therapeutics Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
6.5. Targeted Therapy
- 6.5.1. Global Hematologic Malignancies Therapeutics Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
6.6. Others
- 6.6.1. Global Hematologic Malignancies Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Hematologic Malignancies Therapeutics Market, by End Use

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
7.3. Hospital Pharmacies
- 7.3.1. Global Hematologic Malignancies Therapeutics Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
7.4. Others
- 7.4.1. Global Hematologic Malignancies Therapeutics Market, by Others, by Region, 2020-2034 (USD Billion)

8. Global Hematologic Malignancies Therapeutics Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Hematologic Malignancies Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
8.3. Hematologic Malignancies Therapeutics Market - North America
- 8.3.1. North America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.3.2. North America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.3.3. North America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.3.4. Hematologic Malignancies Therapeutics Market - U.S.
  - 8.3.4.1. U.S.: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.3.4.2. U.S.: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.3.4.3. U.S.: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.3.5. Hematologic Malignancies Therapeutics Market - Canada
  - 8.3.5.1. Canada: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.3.5.2. Canada: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.3.5.3. Canada: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
8.4. Hematologic Malignancies Therapeutics Market - Europe
- 8.4.1. Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.4.2. Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.4.3. Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.4. Hematologic Malignancies Therapeutics Market - UK
  - 8.4.4.1. UK: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.4.2. UK: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.4.3. UK: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.5. Hematologic Malignancies Therapeutics Market - France
  - 8.4.5.1. France: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.5.2. France: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.5.3. France: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.6. Hematologic Malignancies Therapeutics Market - Germany
  - 8.4.6.1. Germany: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.6.2. Germany: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.6.3. Germany: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.7. Hematologic Malignancies Therapeutics Market - Italy
  - 8.4.7.1. Italy: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.7.2. Italy: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.7.3. Italy: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.8. Hematologic Malignancies Therapeutics Market - Spain
  - 8.4.8.1. Spain: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.8.2. Spain: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.8.3. Spain: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.9. Hematologic Malignancies Therapeutics Market - Netherlands
  - 8.4.9.1. Netherlands: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.9.2. Netherlands: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.9.3. Netherlands: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.10. Hematologic Malignancies Therapeutics Market - Russia
  - 8.4.10.1. Russia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.10.2. Russia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.10.3. Russia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.4.11. Hematologic Malignancies Therapeutics Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.4.11.2. Rest of Europe: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.4.11.3. Rest of Europe: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
8.5. Hematologic Malignancies Therapeutics Market - Asia Pacific
- 8.5.1. Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.4. Hematologic Malignancies Therapeutics Market - China
  - 8.5.4.1. China: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.4.2. China: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.4.3. China: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.5. Hematologic Malignancies Therapeutics Market - India
  - 8.5.5.1. India: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.5.2. India: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.5.3. India: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.6. Hematologic Malignancies Therapeutics Market - Malaysia
  - 8.5.6.1. Malaysia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.6.2. Malaysia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.6.3. Malaysia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.7. Hematologic Malignancies Therapeutics Market - Japan
  - 8.5.7.1. Japan: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.7.2. Japan: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.7.3. Japan: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.8. Hematologic Malignancies Therapeutics Market - Indonesia
  - 8.5.8.1. Indonesia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.8.2. Indonesia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.8.3. Indonesia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.9. Hematologic Malignancies Therapeutics Market - South Korea
  - 8.5.9.1. South Korea: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.9.2. South Korea: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.9.3. South Korea: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.10. Hematologic Malignancies Therapeutics Market - Australia
  - 8.5.10.1. Australia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.10.2. Australia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.10.3. Australia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.5.11. Hematologic Malignancies Therapeutics Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.5.11.2. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.5.11.3. Rest of Asia Pacific: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
8.6. Hematologic Malignancies Therapeutics Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.4. Hematologic Malignancies Therapeutics Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.6.4.2. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.6.4.3. Saudi Arabia: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.5. Hematologic Malignancies Therapeutics Market - UAE
  - 8.6.5.1. UAE: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.6.5.2. UAE: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.6.5.3. UAE: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.6. Hematologic Malignancies Therapeutics Market - Israel
  - 8.6.6.1. Israel: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.6.6.2. Israel: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.6.6.3. Israel: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.7. Hematologic Malignancies Therapeutics Market - South Africa
  - 8.6.7.1. South Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.6.7.2. South Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.6.7.3. South Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.6.8. Hematologic Malignancies Therapeutics Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.6.8.2. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.6.8.3. Rest of Middle East & Africa: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
8.7. Hematologic Malignancies Therapeutics Market - Latin America
- 8.7.1. Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.4. Hematologic Malignancies Therapeutics Market - Mexico
  - 8.7.4.1. Mexico: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.7.4.2. Mexico: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.7.4.3. Mexico: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.5. Hematologic Malignancies Therapeutics Market - Brazil
  - 8.7.5.1. Brazil: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.7.5.2. Brazil: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.7.5.3. Brazil: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.6. Hematologic Malignancies Therapeutics Market - Argentina
  - 8.7.6.1. Argentina: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.7.6.2. Argentina: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.7.6.3. Argentina: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)
- 8.7.7. Hematologic Malignancies Therapeutics Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Disease, 2020-2034 (USD Billion)
  - 8.7.7.2. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by Therapy, 2020-2034 (USD Billion)
  - 8.7.7.3. Rest of Latin America: Hematologic Malignancies Therapeutics Market, by End Use, 2020-2034 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. AbbVie Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. Amgen Inc.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Bristol-Myers Squibb Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. F. Hoffmann-La Roche Ltd.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Gilead Sciences Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Johnson & Johnson
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Novartis AG
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Pfizer Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Merck & Co., Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Takeda Pharmaceutical Company Limited
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
10.11. AstraZeneca
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
10.12. BeiGene
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
10.13. Kite Pharma (a subsidiary of Gilead Sciences)
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
10.14. Celgene Corporation (acquired by Bristol-Myers Squibb)
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
10.15. Regeneron Pharmaceuticals, Inc.
- 10.15.1. Company Overview
- 10.15.2. Financial Performance
- 10.15.3. Product Benchmarking
- 10.15.4. Recent Development

血液悪性腫瘍治療薬の世界市場：市場規模・シェア・動向、業界分析 (疾患別・治療法別・最終用途別・地域別)、将来予測 (2025年～2034年)

Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Therapy, End Use, and Region - Market Forecast, 2025-2034

血液悪性腫瘍治療薬市場：分析概要

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章分析手法

第4章血液悪性腫瘍治療薬市場の洞察

第5章世界の血液悪性腫瘍治療薬市場：疾患別

第6章世界の血液悪性腫瘍治療薬市場：治療法別

第7章世界の血液悪性腫瘍治療薬市場：最終用途別

第8章世界の血液悪性腫瘍治療薬市場：地域別

第9章競合情勢

第10章企業プロファイル

List of Tables:

List of Figures:

Hematologic Malignancies Therapeutics Market Report Highlights

By Disease Outlook (Revenue-USD Billion, 2020 - 2034)

By Therapy Outlook (Revenue-USD Billion, 2020 - 2034)

By End Use Outlook (Revenue-USD Billion, 2020 - 2034)

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Hematologic Malignancies Therapeutics Market Insights

5. Global Hematologic Malignancies Therapeutics Market, by Disease

6. Global Hematologic Malignancies Therapeutics Market, by Therapy

7. Global Hematologic Malignancies Therapeutics Market, by End Use

8. Global Hematologic Malignancies Therapeutics Market, by Geography

9. Competitive Landscape

10. Company Profiles

血液悪性腫瘍治療薬の世界市場：市場規模・シェア・動向、業界分析 (疾患別・治療法別・最終用途別・地域別)、将来予測 (2025年～2034年)

Hematologic Malignancies Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Therapy, End Use, and Region - Market Forecast, 2025-2034

血液悪性腫瘍治療薬市場：分析概要

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 分析手法

第4章 血液悪性腫瘍治療薬市場の洞察

第5章 世界の血液悪性腫瘍治療薬市場：疾患別

第6章 世界の血液悪性腫瘍治療薬市場：治療法別

第7章 世界の血液悪性腫瘍治療薬市場：最終用途別

第8章 世界の血液悪性腫瘍治療薬市場：地域別

第9章 競合情勢

第10章 企業プロファイル

List of Tables:

List of Figures:

Hematologic Malignancies Therapeutics Market Report Highlights

By Disease Outlook (Revenue-USD Billion, 2020 - 2034)

By Therapy Outlook (Revenue-USD Billion, 2020 - 2034)

By End Use Outlook (Revenue-USD Billion, 2020 - 2034)

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Hematologic Malignancies Therapeutics Market Insights

5. Global Hematologic Malignancies Therapeutics Market, by Disease

6. Global Hematologic Malignancies Therapeutics Market, by Therapy

7. Global Hematologic Malignancies Therapeutics Market, by End Use

8. Global Hematologic Malignancies Therapeutics Market, by Geography

9. Competitive Landscape

10. Company Profiles

第1章イントロダクション

第2章エグゼクティブサマリー

第3章分析手法

第4章血液悪性腫瘍治療薬市場の洞察

第5章世界の血液悪性腫瘍治療薬市場：疾患別

第6章世界の血液悪性腫瘍治療薬市場：治療法別

第7章世界の血液悪性腫瘍治療薬市場：最終用途別

第8章世界の血液悪性腫瘍治療薬市場：地域別

第9章競合情勢

第10章企業プロファイル